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The Src family kinase inhibitor 
dasatinib delays pain-related 
behaviour and conserves bone in a 
rat model of cancer-induced bone 
pain
Camilla Kristine Appel1, Simone Gallego-Pedersen1, Line Andersen1, Sophie Blancheflor 
Kristensen1, Ming Ding2, Sarah Falk1, Manasi Sayilekshmy1, Charlotte Gabel-Jensen3 & Anne-
Marie Heegaard1
Pain is a severe and debilitating complication of metastatic bone cancer. Current analgesics do not 
provide sufficient pain relief for all patients, creating a great need for new treatment options. The Src 
kinase, a non-receptor protein tyrosine kinase, is implicated in processes involved in cancer-induced 
bone pain, including cancer growth, osteoclastic bone degradation and nociceptive signalling. Here we 
investigate the role of dasatinib, an oral Src kinase family and Bcr-Abl tyrosine kinase inhibitor, in an 
animal model of cancer-induced bone pain. Daily administration of dasatinib (15 mg/kg, p.o.) from day 
7 after inoculation of MRMT-1 mammary carcinoma cells significantly attenuated movement-evoked 
and non-evoked pain behaviour in cancer-bearing rats. Radiographic - and microcomputed tomographic 
analyses showed significantly higher relative bone density and considerably preserved bone micro-
architecture in the dasatinib treated groups, suggesting a bone-preserving effect. This was supported by 
a significant reduction of serum TRACP 5b levels in cancer-bearing rats treated with 15 mg/kg dasatinib. 
Furthermore, immunoblotting of lumbar spinal segments showed an increased activation of Src but not 
the NMDA receptor subunit 2B. These findings support a role of dasatinib as a disease modifying drug in 
pain pathologies characterized by increased osteoclast activity, such as bone metastases.
Pain is a common, feared and serious complication of cancer occurring in more than 70% of patients with 
advanced stage cancer1–3. Bone cancer most often arises when cancerous cells from a primary tumour e.g. breast, 
prostate or lung metastasize to the bone4. In the clinic, patients with cancer-induced bone pain describe the 
pain as heterogeneous and gradually increasing with disease progression5. Current treatment options include 
non-steroidal inflammatory drugs (NSAIDS), opioids and antiresorptive agents such as bisphosphonates1, 6. 
Although opioids have a key role in pain management, opioids are associated with the development of tolerance, 
thereby increasing the required dose, leading to severe adverse effects, including nausea, dizziness, constipation, 
respiratory depression, sedation as well as the risk of addiction6. Other treatment options include radiotherapy or 
radioisotopes7. Radiotherapy has proven to be one of the most efficient treatments for relieving pain in patients 
suffering from uncomplicated bone metastases. Up to 60% of patients receiving treatment report significant pain 
relief and 25% experience complete pain relief7. However, there is a need for improved treatment options and the 
mechanisms underlying cancer-induced bone pain is still not fully understood.
Cancer-induced bone pain contains components of both neuropathic and inflammatory pain but also has 
its own distinctive characteristics making it a unique pain state8, 9. When the tumour grows in the bone it dam-
ages the surrounding nerves and tissue; produces a wide range of cytokines and growth factors; stimulates 
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inflammatory infiltration, and increases bone degradation10, 11. Simultaneously, a reorganization of the central 
nervous system in the areas receiving information from the cancer-bearing area takes place, driving a central sen-
sitization, i.e. increased response and activity of dorsal horn neurons to nociceptive inputs12, 13. The unique neu-
rochemical identity of cancer-induced bone pain may explain why cancer pain often is refractory to traditional 
analgesics14–16. One potential future analgesic target is the non-receptor tyrosine kinase Src which is a member of 
the Src kinase family. Src is a widely expressed kinase potentially involved in several of the processes leading to 
cancer-induced bone pain17–20. Src is encoded by the Src gene and was the first identified proto oncogene. Src has 
been implicated in cancer growth, angiogenesis and metastasis17 and increased expression and activity of Src has 
been correlated to advanced cancer and poor prognosis in a variety of human cancers21, 22. Furthermore, Src is a 
key regulator of normal bone homeostasis18, 23. It is crucial for the resorbing function of osteoclasts23 and targeted 
deletion of the Src gene in mice yields osteopetrotic mice, i.e. mice with increased bone mass18. Finally, Src fam-
ily kinases are ubiquitously expressed in the central nervous system and abundant in neurons24. Src is involved 
in several fundamental signalling pathways, e.g., epidermal growth factor (EGF), extracellular regulated kinase 
(ERK) and EphrinB225, 26. In regards to pain pathologies, Src has been demonstrated to play an important role, 
due to its attachment to the N-methyl-D-aspartate (NMDA) receptor 2B subunit (NR2B) in the NMDA receptor 
complex. Phosphorylation of Src induce phosphorylation of the NMDA receptors which up-regulates the recep-
tor activity and increases its channel open time and its opening probability27–29. It has been shown that activation 
of Src contributes to inflammatory pain through phosphorylation of the NR2B in rats30, 31. Furthermore, Liu 
and colleagues reported in 2008 that blocking the interaction between Src and the NMDA receptor complex 
with a peptide mimicking the amino acid sequence of the unique domain of Src ameliorates inflammatory and 
neuropathic pain32, 33 and recently Felice et al. reported that the multi-kinase inhibitor saracatinib inhibits ther-
mal hyperalgesia in cancer-induced bone pain34. Thus employing a Src kinase inhibitor could be an optimal 
way of targeting cancer-induced bone pain in a multi-targeted manner. Dasatinib is a multi-kinase inhibitor 
approved for the treatment of chronic myeloid leukaemia, imatinib-resistant or -intolerant chronic myelogenous 
leukaemia and Philadelphia positive acute lymphoblastic leukaemia35. Dasatinib is a highly potent inhibitor of 
the Src kinase family as well as other kinases such as BCR-Abl, Fyn, c-Kit, platelet-derived growth factor receptor 
(PDGFR) alpha and –beta, and the ephrin receptor kinase36. Pre-clinically dasatinib has been shown to inhibit 
tumour growth37–39, osteoclast function40 and induce osteoblast activity41, 42. Clinically the effect of dasatinib has 
been studied in solid tumours43, 44 and in combination with zoledronic acid for the treatment of breast-cancer 
bone metastasis45. The latter clinical study concluded that combination therapy was beneficial in hormone 
receptor positive breast cancers in regards to bone response and tumour growth45. Dasatinib is already clini-
cally approved for treatment of chronic myeloid leukaemia and is a well-tolerated therapy. We hypothesize that 
dasatinib treatment could attenuate cancer-induced bone pain. Therefore, using a rat model of cancer-induced 
bone pain, we sought to determine whether inhibition of Src family tyrosine kinases by dasatinib would decrease 
tumour burden, decrease bone degradation, and reduce pain-related behaviours. Using a combination of behav-
ioural, imaging, and immunoblotting assays we show that dasatinib acts as a disease modifier that delays onset of 
cancer-induced bone pain by preserving bone mass.
Results
High dose dasatinib delays onset of pain-related behaviours. To test the analgesic potential of 
dasatinib on cancer-induced bone pain, the limb use test and the weight-bearing test was used to assess pain-re-
lated behaviours. Animals inoculated with mammary cancer cells and treated with vehicle developed a significant 
reduction in limb use score from day 16 (p = 0.0001). Daily oral administration of high dose (15 mg/kg) dasatinib 
significantly delayed the onset of movement-evoked pain demonstrated by a significant difference in limb use 
score on day 16 (p = 0.005) and 18 (p = 0.0103) compared to the vehicle treated cancer-bearing group (Fig. 1a). 
In addition, on day 16 (p = 0.018) and 18 (p = 0.0053) there was a significant difference between the high and 
low dose dasatinib cancer-bearing groups in the limb use test. These data were supported by the weight-bearing 
test. Cancer-bearing animals treated with vehicle demonstrated a significant weight-bearing deficit from day 16 
post inoculation compared to sham-operated rats (p = 0.0005). Rats treated with high dose dasatinib had a sig-
nificantly improved weight-bearing ratio compared to both low dose treated rats (p = 0.0351, day 18) and vehicle 
treated rats (p = 0.0296, day 20) (Fig. 1b). Low dose (5 mg/kg) dasatinib had no effect on development of pain-re-
lated behaviour. The two sham groups did not show pain-related behaviour in any of the two tests.
Dasatinib affects spinal Src phosphorylation but not NMDA receptor subunit 2B phosphoryl-
ation. To investigate if dasatinib inhibits phosphorylation of Src in the spinal cord western blots were per-
formed. Cancer-bearing animals treated with vehicle had a significant increase in Src phosphorylation compared 
to vehicle treated controls (p = 0.0374). Dasatinib significantly reduced the pSrc/Src ratio back to baseline levels 
in both the high (p = 0.0204) and low (p = 0.0256) treatment group (Fig. 2a,b); however this did not translate 
into an effect on phosphorylation of the NR2B. No difference was detected in phosphorylation of NR2B in the 
dasatinib treated groups compared to the control groups in the advanced disease state (Fig. 2c,d). To further test 
whether cancer-induced bone pain is associated with an increased phosphorylation of Src and the NR2B during 
early disease development, western blot analyses were performed on spinal cords from untreated cancer-bearing 
and sham animals on day 7, 12 and 16 post inoculation. The Src level was unchanged (P > 0.05) between cancer 
and sham groups (Fig. 2b), making the pSrc/Src level indicative of the amount of Src phosphorylation. No differ-
ence in pNR2B/NR2B or pSrc/Src ratio was detected between the two groups as disease progressed (Fig. 2e,f) or 
at advanced-stage disease (Fig. 2a and c).
Dasatinib significantly preserves bone mass. To test if the observed delay in pain development was 
mediated by a bone preserving effect of dasatinib, x-ray photos of the ipsilateral tibia were captured on the day 
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of baseline measurements and on day 7, 10, 13, 16, 18, 20, 22 and 23. High dose dasatinib significantly pre-
served the relative bone density on day 18–23 (p < 0.01, Fig. 3a) compared to the cancer vehicle group, suggesting 
that dasatinib prevents bone degradation induced by the cancer. No significant difference in bone density was 
observed between the two cancer-bearing groups treated with different doses of dasatinib or between the two 
sham-operated groups (p > 0.05). The increase in relative bone density for the cancer-operated group treated 
with high dose dasatinib was supported by µCT analyses of the bone (Fig. 4a–e). Post mortem micro-architectural 
analysis of the proximal part of the ipsilateral tibia showed a significantly higher bone surface density of the high 
dose dasatinib treated cancer-bearing animals compared to vehicle treated cancer-operated animals (p = 0.013, 
Fig. 3b) as well as significantly lower trabecular separation (p = 0.0077, Fig. 3c). In addition, cancer-operated 
rats treated with 5 mg/kg dasatinib had significantly lower bone surface-to-volume ratio compared to control 
(p = 0.0242, Fig. 3d). There was no significant difference between the high and low dasatinib dose groups in any 
of the micro-architectural parameters investigated (p > 0.05, Fig. 3b–d).
High dose dasatinib significantly decreased serum TRACP 5b levels. Serum tartrate-resistant acid 
phosphatase 5b was measured on days 6, 12 and 23 post inoculation, hence before and following 6 and 12 days of 
dasatinib treatment, to evaluate the effect of dasatinib on the number of bone-resorbing osteoclasts. High dose dasat-
inib treatment of cancer-bearing animals significantly decreased serum TRACP 5b levels on day 23 compared to the 
vehicle treated controls (p = 0.017, Fig. 5c). Also on day 23 the dasatinib treated sham group had a significant decrease 
in serum TRACP 5b levels compared to the vehicle treated sham group (p = 0.0008). Low dose dasatinib had no sig-
nificant effect on TRACP 5b levels when compared to the vehicle treated cancer controls on day 23 (p > 0.999, Fig. 5), 
and was significantly different from the high dose treated cancer group (p = 0.0014). The cancer-operated vehicle 
group did not show increased TRACP 5b levels compared to the sham-operated vehicle group on any of the test days. 
There was no significant difference between the groups on day 6, i.e. the day before initiation of dasatinib treatment 
(p > 0.999, Fig. 5a). On day 12, after 6 days of dasatinib treatment, however a tendency for the high dose dasatinib to 
reduce serum levels of TRACP 5b compared to vehicle treatment (p = 0.97, Fig. 5b) was observed.
Dasatinib inhibits proliferation of the MRMT1-luc2 mammary carcinoma cells in vitro. The 
effect of dasatinib on tumour proliferation was tested in vitro. Cells were treated with increasing doses (3·10−4–
205 µM) of dasatinib for 48 hours and the metabolic activity of the cells investigated. There was a significant 
decrease in viable cells compared to the untreated control as the concentration of dasatinib increased (Fig. 6a–c). 
The IC50 value for the MRMT1-luc2 cell line in the MTT assay was 0.142 µM with a 95% confidence interval 
(95CI) of [0.061; 0.334]. The results were supported by the BrdU assay and RealTime-Glo™ MT Cell Viability 
Assay, with IC50 values of 0.012 µM 95CI [0.006; 0.026] and 0.072 µM 95CI [0.030; 0.173].
Dasatinib treatment does not affect MRMT1-luc2 mammary carcinoma cell bioluminescent sig-
nal in vivo compared to vehicle treated rats. To test if dasatinib affects the bioluminescent tumour signal 
in vivo bioluminescence was measured over time starting from day 7 post cancer cell inoculation. The biolumines-
cent signal increased over time until it reached a plateau around day 16 (Fig. 7a–c). No significant difference in bio-
luminescent signal was observed among the three cancer-operated groups on any of the test days (p > 0.999, Fig. 7a).
Figure 1. Chronic oral treatment with high dose dasatinib delays onset of skeletal pain-related behaviour in 
the rat model of cancer-induced bone pain. (a) High dose (15 mg/kg) dasatinib induces an anti-nociceptive 
effect on post inoculation day 16 and 18 compared to the control vehicle group, demonstrating a delay in onset 
of movement evoked pain behaviour. (b) Weight-bearing deficits are significantly delayed in the high dose 
dasatinib group compared to the vehicle treated control. Two-way repeated-measurement ANOVA followed by 
Bonferroni’s multiple comparison test revealed statistically significant differences among the groups with regard 
to pain-related behaviors. Data are displayed as mean ± SEM, n = 10–11. #Cancer-operated group treated with 
vehicle compared to sham-operated group treated with vehicle; *Cancer-operated rats treated with 15 mg/kg 
dasatinib compared to the vehicle treated cancer-operated group; ¤Cancer-operated rats treated with 15 mg/kg 
dasatinib compared to cancer-operated rats treated with 5 mg/kg dasatinib.
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Chronic treatment of 30 mg/kg dasatinib induces severe adverse events. The general health status 
of the rats was assessed by determining the use of the cancer-bearing limb, grooming behaviour and by measuring 
body weight every third day (Fig. 8). In the sham-operated group receiving high dose dasatinib (15 mg/kg), 4 out 
Figure 2. Increased spinal cord Src phosphorylation in cancer-induced bone pain is blocked by dasatinib. 
Ratios of spinal expression of phosphorylated Src (pSrc) to total Src (a,e) and phosphorylated NMDA receptor 
subunit 2B (pNR2B) to total NR2B (NR2B) (b,f). (a) Cancer-induced bone pain induces an increase of spinal 
pSrc/Src ratio expression at the time of euthanasia. Both high and low dose dasatinib significantly decreases the 
level of phosphorylation of Src compared to vehicle treated control. B: Representatives of Western Blot. (c) No 
significant changes of spinal pNR2B/NR2b ratio expression were observed between the five treatment groups 
at the time of euthanasia. (d) Representatives of Western Blot. (e,f): Timeline study of cancer-induced bone. No 
significant change in the expression of spinal pSrc/Src (e) or pNR2B/NR2B (f) is observed during development 
of cancer-induced bone pain in the female rat. One-way ANOVA followed by Bonferroni’s multiple comparison 
test. Data are displayed as mean ± SEM, n = 4–10. The blots displayed are cropped and the full-length blots are 
available in the Supplementary Information file.
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of 10 animals exhibited adverse events (e.g. gastro intestinal side effects and fatigue) resulting in euthanasia of 
one rat on day 16 and three on day 20. A higher dose of 30 mg/kg, previously tested by Tokuhisa et al., 2014 for 
advanced extremity melanoma46, was initially included in the study. However, the dose lead to severe adverse 
events (e.g. distension of the gastrointestinal tract with gas/fluid/digesta, weight loss and fatigue) in both sham 
and cancer-operated animals and the animals were euthanized on day 15 or 16. Data from the 30 mg/kg rats have 
hence not been included in the data analyses. The dose of 5 mg/kg dasatinib did not lead to any adverse events.
Discussion
Despite improvement in treatment options, many patients with advanced- or metastatic cancer experience 
unsatisfactory pain relief which severely compromises their quality of life2, 14. Various pre-clinical studies have 
demonstrated that dasatinib significantly inhibits tumour growth and osteoclast function, and increase osteoblast 
activity. Thus, our original hypothesis was that inhibition of Src family tyrosine kinases by dasatinib would reduce 
pain-related behaviour through a decrease in NMDAR mediated central sensitization, tumour burden and bone 
degradation. Indeed, the current study supports a potential therapeutic role for dasatinib in cancer-induced bone 
pain. Administration of 15 mg/kg dasatinib efficiently delayed onset of movement-evoked and non-evoked pain 
compared to the vehicle group in the MRMT-1 model of cancer induced bone pain.
To elucidate the mechanism underlying the analgesic effect of dasatinib kinase inhibition, we tested the 
hypothesis that the delay in pain-related behaviour was induced by inhibition of Src mediated phosphorylation of 
NR2B in the spinal cord. In the dorsal horn, Src holds a critical regulatory role in the generation and maintenance 
of central sensitization through activation of NMDAR function by phosphorylation of the NR2B subunit31, 47. The 
Figure 3. Dasatinib conserves bone mass in cancer-bearing rats. (a) Two-way repeated-measurement ANOVA 
followed by Bonferroni’s multiple comparison test showed that the cancer vehicle group is significant decrease 
in relative bone density compared to the sham operated group on day 13, 18−23. High dose (15 mg/kg) 
dasatinib preserved bone density throughout the experiment compared to vehicle treated cancer control. (b–d) 
Microcomputed tomographic analysis of cancer-bearing tibia analysed by a one-way repeated-measurement 
ANOVA followed by Bonferroni’s multiple comparison test. (b) High dose dasatinib preserves the bone 
surface density compared to the cancer vehicle group. (c) High dose dasatinib treatment lowers the trabecular 
separation significantly compared to the cancer vehicle control group. (d) Low dose dasatinib decreases the 
bone surface-to-volume ratio compared to cancer vehicle control. Data are displayed as mean ± SEM, n = 10–
11. #Cancer-bearing group treated with vehicle compared to sham group treated with vehicle; *Cancer-bearing 
rats treated with 15 mg/kg dasatinib compared to the vehicle treated cancer-bearing group; +Cancer-operated 
rats treated with vehicle compared to cancer-operated rats treated with 5 mg/kg dasatinib.
www.nature.com/scientificreports/
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NR2 subunits of the NMDA receptor complex are involved in binding of glutamate and determine the receptor 
kinetics. The NR2B subunit is predominantly expressed in the superficial dorsal horn and has been identified as 
the key Src-mediated-tyrosine-phosphorylated subunit in the NMDA receptor complex33. It has been proposed 
to be involved in development of spinal plasticity and hyperalgesia after inflammatory and neuropathic pain30, 48 
as well as cancer-induced bone pain49–51. Liu et al. reported that blocking the Src-dependent phosphorylation of 
NMDA through an anchoring protein reversed inflammatory and neuropathic pain32. In this study both doses 
of dasatinib are able to block Src phosphorylation in the spinal cord, however, this effect does not translate into a 
significant effect on the level of NMDA receptor 2B phosphorylation at Tyr1472. Similarly, results by Felice et al.34 
show increased pSrc/Src in the MRMT-1 male rat model of cancer-induced bone pain but did not demonstrate 
an effect on NR2B phosphorylation. Overall, our data indicates that the analgesic effect of high dose dasatinib 
Figure 4. Micro-CT and x-ray images illustrating the proximal part of the tibia of the five different treatment 
groups. Micro CT image captured post-mortem of (a) cancer-operated and treated with vehicle; (b) Cancer-
operated and treated with 5 mg/kg dasatinib; (c) Cancer-operated and treated with 15 mg/kg dasatinib; (d) 
Sham-operated and treated with vehicle; and (e) Sham-operated and treated with 15 mg/kg dasatinib. X-ray 
images captured on day 22 post inoculation f) cancer-operated and treated with vehicle; (g) Cancer-operated 
and treated with 5 mg/kg dasatinib; (h) Cancer-operated and treated with 15 mg/kg dasatinib; (i) Sham-
operated and treated with vehicle; and (j) Sham-operated and treated with 15 mg/kg dasatinib.
Figure 5. High dose dasatinib significantly lowers serum levels of TRACP 5b compared to vehicle treated 
controls. (a) There is no significant difference between the groups on day 6, i.e. one day before starting dasatinib 
treatment. (b) There is no significant difference between the groups on day 12, i.e. after 6 days of dasatinib 
treatment. (c) Serum TRACP 5b is significantly decreased in the high dose dasatinib treated groups compared 
to vehicle treated controls on day 23 post inoculation. Low dose dasatinib does not influence the serum TRACP 
5b values compared to vehicle treated control. Ordinary one-way repeated-measurement ANOVA followed by 
Bonferroni’s multiple comparison test. The results are shown as the mean ± SEM, n = 10–11.
www.nature.com/scientificreports/
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treatment does not result from inhibiting Src phosphorylation at the spinal cord level, but rather from a dis-
ease modifying effect on the bone and possibly an anti-proliferative effect on the tumour, causing an indirect 
anti-nociceptive effect. However, even though dasatinib has high selectivity for Src and the other SFKs, e.g. Fyn, 
Lck, Yes as well as the Bcr-Abl kinase, dasatinib is a multi-kinase inhibitor and also targets several other kinases 
such as c-kit, PDGFRβ, p38 mitogen-activated protein kinase, Her1, Her2 and FGFR-136. One or several of these 
kinases may convey specific or unspecific anti-nociception. c-kit is for example expressed in lamina I and II of the 
dorsal horn and reported to be involved in development of persistent nociceptive pathways upstream from Src52, 
53. Likewise, p38 mitogen-activated protein kinase and FGFR-1 are also reported to have roles in different pain 
pathologies, including cancer-induced bone pain54–56. It is therefore not possible to exclude a non-Src mediated 
anti-nociceptive effect of dasatinib.
Dasatinib has been demonstrated to have an inhibitory effect on the growth of several cancer types both in 
vitro and in vivo39, 57–59. Korenckji and others reported that dasatinib inhibits prostate cancer growth in bone in 
mice60. We therefore hypothesized that the delay in onset of pain was mediated by a lower tumour burden in the 
dasatinib-treated animals. The effect of dasatinib on the MRMT1-luc2 cell line has not previously been evaluated. 
Figure 6. Dasatinib inhibits cell proliferation in MRMT1-luc2 cells in a dose-dependent manner in vitro. 
MRMT1-luc2 cells were treated with increasing concentrations of dasitanib for 48 h and assayed by the (a) MTT 
assay, (b) the BrdU assay, and (c) the RealTime-Glo™ assay. IC50, the concentration needed to inhibit viability 
or proliferation by 50. Data were normalized to cells treated with 0.1% DMSO (negative controls, 100% activity) 
and blank controls, e.g. wells without cells (0% activity) and expressed as percentage of these controls. Data are 
displayed as mean ± SEM. Normalized response is compared to common log of dasatinib concentration (µM) 
and the IC50 calculated using a variable slope. Data from the MTT assay represents one of three independent 
experiments done in quadruplicates. Data from the BrDU and RealTime-Glo™ assays represents one 
experiment done in triplicates to confirm the results from the MTT assay.
Figure 7. Bioluminescence signal from cancer cells in vivo. (a) The signal increases in all groups during the 
first 16 days until it reaches a plateau. Two-way repeated-measurement ANOVA followed by Bonferroni’s 
multiple comparison test did not reveal any statistically significant differences between the treatment groups 
when compared to vehicle on any of the test days (p < 0.05). Data are displayed as mean ± SEM, n = 10–11. 
Bioluminescent overlay on bright field images (b) example of low bioluminescent signal 7 days post inoculation 
and (c) example of high bioluminescent signal 19 days post inoculation.
www.nature.com/scientificreports/
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In vitro treatment of MRMT-1 mammary carcinoma cells with dasatinib significantly inhibited cell proliferation 
and viability in the MTT assay in a concentration-dependent way. As the reliability of the MTT assay for testing 
similar drugs, such as imatinib, has been questioned61, 62, the in vitro effect of dasitinib was in addition tested 
using the RealTime-Glo™ MT Cell Viability Assay and BrdU assay. Both assays supported an inhibitory effect of 
dasatinib on MRMT-1 cancer cell viability and proliferation in vitro. However, in vivo bioluminescent imaging 
did not suggest any decrease in signal after treatment with dasatinib. In all groups the bioluminescent signal 
increased in the initial 16 days before reaching a plateau. When the signal reach the plateau phase it is likely 
that the value of bioluminescence is limited when estimating tumour volume of large, necrotic tumours due to 
lack of oxygen and ATP, and hence it cannot be excluded that dasatinib had an anti-proliferative effect on the 
tumour burden in vivo. Overall, the reported results on the MRMT1-luc2 cell line in vitro and in vivo suggests a 
correlation with previous data where dasatinib was shown to inhibit proliferation of cancer cell lines in vitro39, 63, 
however an effect that did not translate in vivo63 or to the clinic45, 64.
Lastly, we tested if the delay in pain-related behaviours was mediated by a bone mass preserving effect of 
dasatinib. In accordance with this hypothesis we here report a bone preserving effect of dasatinib supported by 
both x-ray images during the disease progression and µCT analyses post mortem. Moreover, high dose dasati-
nib induced a decrease in the osteoclast marker TRACP 5b which reflects the number of osteoclasts65. This is 
supported by clinical data44 reporting a decrease in bone resorption markers, NTx and TRACP-5b of 46.3% and 
22.2%, respectively, after treatment with dasatinib and zoledronic acid. Previous results in Src knockout mice 
demonstrated that after depletion of Src the function of osteoclasts were diminished because full maturation of 
the osteoclast was inhibited. However, depletion of Src does not decrease the amount of osteoclasts in the bone 
microenvironment18, 23. This indicates that the suggested reduction in osteoclast number seen after treatment 
with dasatinib is not due to inhibition of Src kinase activity. The reduction in the osteoclast number could how-
ever also be mediated through the inhibiting effect of dasatinib on other tyrosine kinases, such as macrophage 
colony-stimulating factor receptor (c-fms) activation66. Signalling through c-fms is crucial for the proliferation 
and survival of osteoclasts. Likewise dasatinib also decrease expression of receptor activator of nuclear factor 
kappa B ligand (RANKL)67 - a crucial factor for osteoclast differentiation and activity. Additionally, the bone pre-
serving effect observed can be mediated by an anabolic effect of dasatinib. Low dasatinib concentrations enhance 
osteoblastogenesis possibly through Src inhibition42. Among several Src family kinases only Src is synthetized 
and expressed in its activated form in osteoblasts. Src is therefore thought to have a dominant role in regulating 
osteoblast activity and knockdown of Src leads to decreased osteoblast proliferation and increased osteoblast 
differentiation42.
Only one other pre-clinical study has addressed the effect of multi-kinase inhibition on cancer-induced 
bone pain. As mentioned above, Felice and colleagues showed that daily oral administration of the multi-kinase 
inhibitor saracatinib, reversed thermal hyperalgesia, but not mechanical allodynia following inoculation of 3·103 
MRMT-1 cancer cells34. However, the study did not assess movement-evoked or weight-bearing induced pain 
and terminated the experiment 13 days post cancer cell inoculation, thereby only testing the analgesic potential 
in the early phase of pain development. The current study report the effect of Src inhibition in both the early stage 
and in in the more progressed stage of bone cancer pain and finds a delay in onset of pain-related behaviours post 
inoculation of 5·103 MRMT-1 cells, thus supporting the finding by Felice et al.
The lack of anti-nociceptive effect of dasatinib in the advanced stage of the disease could be explained by 
the fast progressing disease phenotype. Bone micro-architectural results suggest that dasatinib slows down the 
pathological processes of cancer-induced bone pain by preserving the bone mass. However, the pain increases as 
the disease progresses towards the advanced stage. This might be due to a tumour-induced hyperinnervation or 
cancer-induced nerve compression/destruction, that counterbalance the bone preserving effect and consequently 
the indirect anti-nociceptive effect of the preserved bone mass is overruled by other pro-nociceptive mechanisms 
in the advanced stage of the disease. Similarly, other treatments with bone preserving effect such as bisphospho-
nates or denosumab do not prevent the progression of metastatic bone pain in advanced stages of the disease 
despite an antiresorptive effect68, 69. Also, studies have reported a non-persistent anti-nociceptive effect when 
administering drug candidates chronically in animal models of cancer-induced bone pain70, 71. Even morphine, 
Figure 8. Dasatinib did not lead to loss of body weight. Two-way repeated-measurement ANOVA followed 
by Bonferroni’s multiple comparison test did not reveal any statistically significant differences among cancer 
bearing and sham-operated animals or between the dasatinib-treated groups (p < 0.05). Data are displayed as 
mean ± SEM, n = 10–11.
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 4792  | DOI:10.1038/s41598-017-05029-1
which is commonly used in the clinic to treat cancer-induced bone pain have limited effect on pain-behaviour 
in the advanced stage of the disease. Animal studies have reported that the anti-nociceptive effect of morphine 
is reduced in cancer compared to other pain models72. Even though morphine is efficient in the early stages 
of cancer-induced bone pain, the anti-nociceptive effect is reduced in the advanced stage of the disease when 
administered in tolerable doses73–75.
A recent published randomized clinical trial also suggests a lack of effect of dasatinib on pain in late stage 
metastatic breast cancer. In the study by Schott el al. dasatinib was administered as 100 mg once daily, or 70 mg 
twice daily to patients with bone-predominant metastatic breast cancer. No effect on progression free survival 
or patient-reported pain was found64. This is comparable to our findings in the animal model and to the lack of 
analgesic effect observed when patients with advanced stages of bone metastases are treated with zoledronic acid 
and denosumab68.
In conclusion, in the current study we show that dasatinib delays onset of movement and non-evoked 
pain-related behaviour in the MRMT-1 Sprague Dawley rat model of cancer-induced bone pain. The effect is 
most likely due to disease modifying properties of dasatinib. Dasatinib, a multi-kinase inhibitor, preserves bone 
integrity in cancer-bearing animals leading to a delay in onset of nociceptive behaviour. These findings support 
a role of dasatinib in pathologies characterized by increased osteoclast activity, such as bone metastases. Indeed 
dasatinib has proven clinically efficient response in bone in combination treatment with zoledronic acid for the 
treatment of breast cancer metastases to bone45. However, dasatinib treatment does not eliminate development of 
pain-related behaviours in the advanced stage of the animal model, corresponding to the advanced-stage meta-
static disease of the patients in the clinical trial by Schott et al., but merely delays the onset of pain. From a clinical 
point of view one might argue that the effect of dasatinib on bone preservation does not prove more beneficial 
compared to already clinically approved treatment options such as radiotherapy or bisphosphonates. Indeed zole-
dronic acid and dasatinib have similar mechanisms of action on rat bones40. Bisphosphonates inhibit osteoclast 
maturation and function and cause osteoclast apoptosis and compared to the anti-neoplastic dasatinib, they gen-
erally cause less severe side effects. Furthermore, several bisphosphonates, e.g. zoledronic acid and ibandronate 
have been proven effective in reducing bone pain in patients with bone metastases and maintained low bone pain 
scores for up to several years76.
Methods
Animals and housing. 6 weeks old female Sprague-Dawley rats weighing 150–170 g (Taconic M&B A/S, 
Denmark) were group-housed in cages of 5 under a 12:12 h light-dark-cycle, in a climate-controlled room, 
with ad libitum access to food and water. The animals were allowed to acclimatize 1–2 weeks before starting the 
experiments. The general health condition of each rat was checked regularly and the body weight was measured 
every third day all through the experiment. Experiments were approved by the Danish Animal Experiments 
Inspectorate, The Danish Veterinary and Food Administration, Ministry of Environment and Food (license no. 
2014-15-0201-00031 C4) and conducted under the guidelines of the International Study of Pain77. All experi-
ments and data analysis were blinded for the researchers.
Cell line culturing and preparation for surgery. The mammary rat metastasis tumour cells-1 trans-
fected with the luciferase gene, MRMT1-luc2, were cultured as previously described for the MRMT-1 cells78, 79. 
Briefly, MRMT1-luc2 were cultured in RPMI-1640 free of glutamine and phenol red (Gibco, Life Technologies 
Europe BD, Denmark) with 5% penicillin-streptomycin-glutamine (10,000 Units/mL, 10,000 µg/mL and 29.2 mg/
mL respectively) (Gibco, Life Technologies Europe BD, Denmark) and 10% heat-inactivated foetal bovine serum 
(Gibco, Life Technologies Europe BD, Denmark) and maintained at 37 °C with 5% CO2. On the day of cancer 
inoculation the cells were washed twice with phosphate buffered saline (no Mg2+, no Ca2+), trypsinized with 0.1% 
w/v Trypsin-EDTA (Gibco, Life Technologies Europe BD, Denmark), centrifuged at 220 g for 3 minutes, washed 
twice with Hank’s balanced salt solution (HBSS) (Gibco, Life Technologies Europe BD, Denmark), counted and 
suspended in a HBSS solution of 5·105 cells/ml. The cells were kept on wet ice until use. The cells prepared for in 
vitro cell assays were washed with medium instead of HBSS.
Cancer-induced bone pain model. The cancer-induced bone pain model was performed as previously 
described78. Shortly, the rat was anaesthetized with 2–4% inhalation isoflurane (Baxter A/S, Allerød, Denmark), 
administered Rimadyl (s.c. 5 mg/kg, Pfizer, Denmark) and placed on its back and confirmed free of reflexes. The 
anterior surface of the right tibia was shaved and disinfected with 70% v/v ethanol. A small incision was made 
with a scalpel on the anterior medial side of the tibia and the tibia was thereafter cautiously exposed and cleaned 
with a cotton swab. Using a 0.7 mm dental drill a hole was made in the tibia and a thin polyethylene tube (outer 
diameter 0.61 mm) (Smiths medical, Denmark) inserted 1 cm into the medullary cavity towards the proximal 
part of the bone and 5·103 cells in 10 µL HBSS was injected using a Hamilton syringe. Sham animals were injected 
with 10 µL HBSS alone. After 1 minute the polyethylene tube was removed and the hole closed with dental cement 
(IRM, Dentsply, Konstanz, Germany), the wound cleaned with isotonic saline, closed with metal clips (Kruuse, 
Denmark) and applied topically with 2% lidocaine gel (AstraZeneca, Denmark). The animal was placed to awake 
under a heat lamp and thereafter placed in their home cage.
In vivo experiments. Treatment study. 52 female Sprague-Dawley rats were randomized according to 
bodyweight into the following five treatment groups. Group 1, 2 and 3 was inoculated with MRMT1-luc2 and 
received vehicle (n = 10), 5 mg/kg dasatinib (n = 11) or 15 mg/kg dasatinib (n = 11), respectively. Group 4 and 5 
underwent sham surgery and were treated with vehicle (n = 10) or 15 mg/kg dasatinib (n = 10), respectively. The 
vehicle was a sterile mix of 80 mM citric acid and 80 mM sodium citrate with a final pH of 3.1. Drug or vehicle 
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treatment was administered every morning, minimum 60 minutes before behavioural testing, by oral gavage 
starting from day 7 post inoculation.
The rats were introduced to the behavioural tests twice before baseline measurements in order to avoid 
stress-induced bias of the behaviour readouts. Behavioural tests were performed two days before surgery and on 
day 7, 10, 13, 16, 18, 20, 22 and 23 post inoculation of MRMT1-luc2 mammary carcinoma cells.
Timeline study. 75 female Sprague-Dawley rats were assigned into the following three groups: naïve (n = 15), 
cancer-operated (n = 30) or sham-operated (n = 30). One third of the animals from each group were euthanized 
on post inoculation day 7, 12 and 16. Behavioural tests and in vivo imaging were performed on day 7, 12 and 16.
Limb use test. All animals from one home cage was transferred to a transparent empty plastic box 
(500 mm × 300 mm × 500 mm) and allowed to familiarize themselves to the new environment for 10 minutes. 
After the habituation all rats were observed individually in the plastic box for 3 minutes and the gait of the affected 
leg was scored using an in-house scoring system validated for inter-experimenter variability. The scale ranged 
from 3 to 0 where; 3 was normal use of the cancer-bearing limb; 2 was a slight limp but normal body distribution; 
1 was a significant limp and a shift in body distribution toward the healthy limb; 0 was a partly lack of use of the 
cancer-bearing limb defined as holding the hind limb aloft while in locomotor activity and/or sitting.
Weight-bearing test. The rats were placed in an incapacitance tester (MJS Technology Ltd., Buntingford, 
Herfordshire, UK) with the hind legs resting on two separate weights while the front legs were resting on the wall 
of the incapacitance tester. The individual load of each hind limb was measured for 4 seconds and measurements 
performed in triplicates. The average weight-bearing ratio was calculated as the amount of weight placed on the 
cancer-bearing leg divided by the total amount of weight put on both legs.
Bioluminescent imaging. The rat was anesthetized with 2–3% inhalation isoflurane (Baxter A/S, Allerød, 
Denmark), and injected intra-peritoneal with 40 mg/kg D-luciferin (PerkinElmer, Denmark) dissolved in PBS. 
10 minutes after injection the animal was transferred to the IVIS® Lumina XR (Caliper Life Sciences, USA) and 
placed on its back. Bioluminescent image settings were as followed; binning: M(4); F/stop: 1 and exposure times 
was adjusted according to the signal and varied from 1 s to 120 s. Three images were taken per animal and the 
animal was repositioned between each image in order to avoid bias. The ROI threshold was set to 35% and the 
signal was recorded in radiance as photons/s/cm2/sr.
X-ray capturing and analysis. An x-ray image of the ipsilateral tibia was taken immediately following the 
bioluminescent images. The tibia was placed next to an aluminium wedge which was used as a control for com-
parison of the relative bone density of the tibia between images. The x-ray image was analysed using NIH ImageJ 
(ImageJ, 1.47 v). The greyscale value of the proximal trabecular part of the tibia was measured and an average of 
the surrounding tissue was subtracted and normalized to the constant aluminium wedge.
Microcomputed tomography. Sprague-Dawley rats treated with dasatinib or vehicle were briefly anesthe-
tized with 4% inhalation isoflurane and euthanized by decapitation. The ipsilateral tibia was removed and fixated 
in 4% paraformaldehyde (PFA) for 7 days and thereafter stored in phosphate buffered saline containing 0.1% PFA 
and 0.1% NaN3 at 4 °C. In order to quantify the tumour-induced osteolysis, the proximal tibia section was scanned 
with a high-resolution microcomputed tomographic (μCT) system (vivaCT40; Scanco Medical AG, Brüttisellen, 
Switzerland), with a spatial 3-dimensional (3D) reconstruction of cubic voxel sizes of 12.5 × 12.5 × 12.5μm3. Each 
3D image dataset consisted of approximately 210 μCT slide images of which 100 slide images (1250μm) were used 
for analysis of bone tissue (2048 × 2048 pixels) with 16-bit grey levels. Bone volume fraction (BV/TV), bone sur-
face to bone volume ratio (BS/BV), and trabecular separation (TbSp) were calculated based on assumption-free 
3D methods80.
Western blot. Timeline study. At the end of the experiments all rats were anesthetized with 4% isoflurane 
and euthanized by decapitation. The spine was exposed and cut free at the sacral and thoracic segments and the 
spinal cord was flushed out from the caudal side using an 18 G blunt needle and sterile isotonic saline. The seg-
ment of the spinal cord correlating to L2-L5 was isolated, divided into an ipsi- and contralateral part, snap frozen 
on dry ice, and stored at −80 °C.
Treatment study. After decapitation, the back of the rat was disinfected with 70% v/v ethanol and a mid-sagittal 
incision was made with a scalpel, the skin removed and the spine made visible. The tissue surrounding the spinal 
cord was removed (Allgaier Instruments GmbH, Frittlingen, Germany) thereby exposing the spine. Using a scis-
sor a transversal cut was made at the rostral end of the spine in order to expose the spinal cord. The dorsal part of 
the spine was then removed from the thoracic part and continuing to the end of the lumbar section. The segment 
of the spinal cord correlating to L2-L5 was isolated, divided into ipsi- and contralateral part, snap frozen on dry 
ice, and afterwards stored at −80 °C.
Each spinal cord segment was weighed and homogenized in a 1 g to 30 mL ratio of solubilisation buffer pH 6.8 
(50 mL of pre-solubilisation buffer containing 0.985% Tris-Hcl, 2% (w/v) Sodium Dodecyl Sulphate and deminer-
alized H2O mixed with 1 tablet cOmplete™ Protease Inhibitor Cocktail (Roche Diagnostics GmbH, Mannheim) 
and 5 tablets PhosSTOP™ Phosphatase Inhibitor Cocktail Tablets (Roche Diagnostics GmbH, Mannheim)). After 
the first homogenization round the samples were stored at 4 °C for 3 h, homogenized again, stored for 30 min at 
4 °C and finally centrifuged for 30 min at 20,000 g at 4 °C. The supernatant was collected and stored at −80 °C 
until use.
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Samples were thawed on wet ice, diluted 1:1 in 2x loading buffer with 5% mercaptoethanol and boiled for 
5 min. 12 µL of each sample were loaded per well on a 7.5% Criterion™ TGX Stain-Free™ Protein Gel, 26 well, 
15 µl (Biorad, Hercules, CA) and blotted onto a PVDF membrane (Biorad, Hercules, CA) using the Biorad 
Trans-Blot® Turbo™ Transfer system set to 2.5 A, 25 V for 35 min. The membrane was washed with TBS-T and 
blocked with 5% (w/v) Bovine Serum Albumin (Sigma-Aldrich, Brøndby, Denmark) which was also used for 
incubation with all antibodies. Blots were incubated overnight at 4 °C and incubated with the following anti-
bodies: Phospho-Src Family (Tyr416) Antibody #2101, 1:100 (Cell Signaling Technology, Massachusetts, USA); 
c-Src Antibody (SRC 2): sc-18 1:1000 (Santa Cruz Biotechnology, Texas, USA); Phospho-NMDAR2B (Tyr1472) 
Antibody #4208 1:1000 (Cell Signaling Technology, Massachusetts, USA); NMDAR2B Antibody #4207 1:1000 
(Cell Signaling Technology, Massachusetts, USA). After washing with TBS-T blots were incubated 1 h with 
(1:2,000) Goat Anti-Rabbit IgG H&L (HRP) ab6721 (Abcam) and developed for 1 minute in the Western 
Lightning ECL Pro kit (PerkinElmer). The signal was detected and subsequently analysed in the Molecular 
Imager® ChemiDoc™ XRS Imaging System with Quantity One software (Bio-Rad).
ELISA analyses of TRACP 5b in rat serum. Serum samples were collected from the rats of the treatment 
study on day 6, 12 and on the day of euthanasia. Animals were fasted for 6 hours before serum collection. 600 µL 
blood was collected from the sublingual vein, stored in microcentrifuge tubes at room temperature for 15–30 min, 
and thereafter centrifuged at 4600 rpm for 10 min at 4 °C. The supernatant was collected and stored at −80 °C 
until analysis.
Osteoclast-derived tartrate resistant acid phosphatase form 5b (TRACP 5b) levels were quantified in rat serum 
by ELISA using the RatTRAPTM Assay, SB-TR102 (Immunodiagnostics Systems Nordic a/s, Herlev, Denmark). 
The assay was performed as described by the manufacturer (Immunodiagnostics Systems Nordic a/s, Herlev, 
Denmark). Samples were diluted 1:4 in isotonic saline, run in duplicates and the absorbance measured at 405 nm 
using a Versa Max microplate reader (Molecular Devices, LLC., California, USA).
Cell viability assays. Cell proliferation and viability was investigated in vitro using the CellTiter 96® 
Non-Radioactive Cell Proliferation Assay (MTT) (Promega, Nacka, Sweden), cell proliferation ELISA, BrdU 
(colorimetric) kit (Roche Diagnostics GmbH, Mannheim, D), and the RealTime-Glo™ MT Cell Viability Assay 
(Promega, Nacka, Sweden). For all assays MRMT1-luc2 cells were harvested, as described above, and 1000 
cells/well was plated in a 96 well plate in 99 µL RPMI-1640 no glutamine, no phenol red medium (Gibco, Life 
Technologies Europe BD, Denmark). After incubation at 37 °C with 5% CO2 for 24 h 1 µL dasatinib was added 
in decreasing concentrations (3·10−4–205 µM) dissolved in dimethylsulfoxide (DMSO) and incubated for addi-
tional 48 h. The MTT assay was performed three times and all measurements were performed in quadruplets. 
Incubation time with dye in the MTT assay was set to 3 h. All measurements for RealTime-Glo™ and the BrdU 
assays were performed in triplicates. The assays were performed as described by the manufacturers. For the BrdU 
assay the labelling time for BrdU was set to 8 h, FixDenat incubation was 30 min and Substrate solution incuba-
tion time was 5 min. In the RealTime-Glo™ assay the Continuous-Read Method was chosen, and the biolumi-
nescent measured at 1000 ms in white, flat bottomed 96 well plates. For all assays the EC50 values were calculated 
using GraphPad Prism® software, version 6 (GraphPad Software, La Jolla, CA, USA)
Statistical analyses. Statistical analyses were performed in GraphPad Prism (version 6; GraphPad Software, 
CA, USA). A 95% confidence interval was chosen as a measure of statistical significance, p > 0.05. The mul-
tiplicity adjusted p value is noted in the text. In the figures, the asterisks denote the following level of signifi-
cance: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Data are displayed as means and the standard error 
of the mean ( ± SEM). Behavioural data were analysed by a two-way repeated-measures ANOVA followed by 
Bonferroni’s multiple comparison test for significance at individual time points. Changes in serum TRACP 5b 
marker and bone microarchitecture were analysed by a one-way ANOVA followed by Bonferroni’s post-hoc test. 
For western blot data outliers were identified by the ROUT method which identify outliers from nonlinear regres-
sion, Q was set to 1%. Western blot results where then analysed by one-way ANOVA followed by Bonferroni’s 
post-hoc test. If an animal, due to reaching of a humane endpoint (defined as limb use score of 0 or weight loss 
above 20%), was euthanized before day 23, the last measurements were carried forward to the following measur-
ing days and used for data analyses.
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